Johns Hopkins HIV Guide
Voriconazole
Voriconazole is a topic covered in the Johns Hopkins HIV Guide.
To view the entire topic, please log in or purchase a subscription.
Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Voriconazole is FDA approved for the following indications in adults and pediatrics ≥ 2 years of age:
- Invasive aspergillosis
- Serious infections caused by Scedosporium apiospermum (Pseudallescheria boydii) and Fusarium spp. (including F. solani) in patients intolerant of, or refractory to, other therapies.
- Esophageal candidiasis
- Candidemia in non-neutropenic patients and other deep tissue Candida infections
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Prophylaxis of invasive aspergillosis and disseminated candidiasis in severely immunocompromised hosts
- Based on in-vitro data and limited clinical experience, voriconazole may be effective for infections due to certain dematiaceous fungi (C. immitis)
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
FDA
- Voriconazole is FDA approved for the following indications in adults and pediatrics ≥ 2 years of age:
- Invasive aspergillosis
- Serious infections caused by Scedosporium apiospermum (Pseudallescheria boydii) and Fusarium spp. (including F. solani) in patients intolerant of, or refractory to, other therapies.
- Esophageal candidiasis
- Candidemia in non-neutropenic patients and other deep tissue Candida infections
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Prophylaxis of invasive aspergillosis and disseminated candidiasis in severely immunocompromised hosts
- Based on in-vitro data and limited clinical experience, voriconazole may be effective for infections due to certain dematiaceous fungi (C. immitis)
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: January 8, 2022
Citation
Avdic, Edina. "Voriconazole." Johns Hopkins HIV Guide, 2022. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545220/3.3/Voriconazole.
Avdic E. Voriconazole. Johns Hopkins HIV Guide. 2022. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545220/3.3/Voriconazole. Accessed March 30, 2023.
Avdic, E. (2022). Voriconazole. In Johns Hopkins HIV Guide https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545220/3.3/Voriconazole
Avdic E. Voriconazole [Internet]. In: Johns Hopkins HIV Guide. ; 2022. [cited 2023 March 30]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545220/3.3/Voriconazole.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Voriconazole
ID - 545220
A1 - Avdic,Edina,Pharm.D.
Y1 - 2022/01/08/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545220/3.3/Voriconazole
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
